ASH Annual Meeting and Exposition | Conference

Intensive Remission Induction Chemo Prior to alloHCT Does Not Confer Survival Advantage in R/R AML

December 10th 2022

Watchful waiting followed by sequential conditioning prior to allogeneic hematopoietic cell transplantation provided similar overall survival and leukemia-free survival to that achieved with intensive remission induction chemotherapy comprised of high-dose cytarabine and mitoxantrone followed by allogeneic hematopoietic cell transplantation in patients with relapsed or refractory acute myeloid leukemia.

Glofitamab/Obinutuzumab Regimen Produces Early, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

December 10th 2022

Glofitamab administered as a fixed 12-cycle regimen 7 days after obinutuzumab pretreatment elicited high, early, and durable responses in patients with relapsed/refractory mantle cell lymphoma who had undergone prior BTK inhibitor therapy.

Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022

December 8th 2022

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple Myeloma

December 17th 2021

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

APVO436 Demonstrates Manageable Safety With Anti-Neoplastic Activity in Relapsed/Refractory AML/MDS

December 15th 2021

The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome, according to updated findings from an ongoing phase 1 trial.

Amphiregulin Represents Potentially Predictive Biomarker in Acute GVHD

December 15th 2021

Elevated amphiregulin was associated with increased mortality risk in acute graft–versus-host-disease, according to a sample of 2 prospective clinical trials showed.

Daratumumab Plus RVd Demonstrates Sustained Improvements in Response in Newly Diagnosed Multiple Myeloma

December 15th 2021

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.

CRS and Interventional Steroids Bare No Adverse Effect on Outcomes With the CD3/CD123 Bispecific Antibody APVO436 in AML/MDS

December 15th 2021

Treatment with the CD123- and CD3-engaging bispecific antibody APVO436 caused cytokine release syndrome in approximately 1 of 5 patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome but was generally well managed with steroids.

Liso-Cel Improved QoL vs SOC in Second-Line Treatment of Relapsed or Refractory LBCL

December 15th 2021

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

Cilta-cel Elicits Early, Deep Responses in Heavily Pretreated, Lenalidomide-Refractory Myeloma

December 15th 2021

A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.

Maintenance Oral Azacitidine Shows Sustained Survival Benefit in AML in First Remission

December 14th 2021

The utilization of oral azacitidine as maintenance treatment in patients with acute myeloid leukemia in first remission following intensive chemotherapy continued to showcase a survival benefit over placebo.

Cilta-Cel Demonstrates Durable Responses at 2 Years Across Multiple Subgroups in R/R Myeloma

December 14th 2021

Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.

Dr. Burke on POLARIX Data Examining a Polatuzumab Vedotin–Based Regimen in Newly Diagnosed DLBCL

December 14th 2021

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Dr. Martin on the 2-Year Follow-Up Results of the CARTITUDE-1 Study in R/R Multiple Myeloma

December 14th 2021

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Efficacy of Cevostamab Increases With Higher Doses in Heavily Pretreated Multiple Myeloma

December 14th 2021

Cycle 1 double step-up dosing with cevostamab demonstrated encouraging activity with effective cytokine release syndrome mitigation in patients with heavily pretreated relapsed/refractory multiple myeloma, supporting further development of the dual-targeted bispecific antibody.

Toxicity Burden Decreased With Acalabrutinib Vs Ibrutinib in CLL

December 14th 2021

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.

Acalabrutinib Shows Superior PFS, Safety Over Other Treatments in Relapsed/Refractory CLL

December 14th 2021

Acalabrutinib demonstrated an advantage in quality-adjusted survival compared with other treatments for relapsed/refractory chronic lymphocytic leukemia.

Magrolimab Plus Various Anti-Leukemia Therapies Being Studied for Efficacy in AML

December 14th 2021

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

High-Frequency Low-Dose Acalabrutinib/Rituximab Combo Elicits 100% ORR in Frontline CLL/SLL

December 14th 2021

High-frequency low-dose acalabrutinib and rituximab represents a feasible and effective combination for the treatment of patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pacritinib Shows Manageable Safety Profile in Cytopenic Myelofibrosis, Severe Thrombocytopenia

December 14th 2021

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

NEXT PAGE
PREVIOUS PAGE
x